The FDA's Drugs@FDA database lists a supplement dated 8 September to an abbreviated new drug application for triamcinolone acetonide held by Micro Labs. The entry does not say which formulation the application covers or what the supplement changes.
Generic application supplements usually concern manufacturing, packaging or labelling updates to match the reference product. Nothing in the record indicates a new safety finding or indication.
There is no change to practice. It is noted here because the regulatory watch recorded it for this desk; prescribers using triamcinolone in any form should continue to follow current labelling.
- The 8 September entry is a supplement to a generic application; formulation and change are not stated.
- No new safety communication accompanies the record.
- No change to prescribing is needed on the basis of this entry.
Why it matters
It records regulatory activity without implying a clinical change that has not happened.
Don't overread it
A generic-application supplement is administrative, not a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for pulmonology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free